Skip to content

Comparison of the Moussa Intraocular Lens Formula to contemporary formulas in a multicenter study.

Oct 2026 · Journal of cataract and refractive surgery · 0 citations
Medicine

Abstract

Purpose

To evaluate the refractive predictive accuracy of the Moussa intraocular lens (IOL) formula compared with Kane, EVO, PEARL-DGS, K6, Hoffer-QST, and Barrett Universal II (BUII).

Setting

Birmingham Midland Eye Centre (Birmingham), Manchester Royal Eye Hospital and Newmedica (Manchester), UK.

Design

Multicenter, retrospective, consecutive, nonrandomized observational case series (September 2022-June 2025).

Methods

Included were one eye per patient undergoing uncomplicated phacoemulsification. Preoperative biometry used the IOLMaster 700, Lenstar LS900, or Pentacam AXL Wave. Lens-constants were optimized to zero mean prediction error (PE) for each formula and lens-biometer combination. Primary outcome was mean absolute error (MAE), evaluated using heteroscedastic studentized bootstrap analysis (2000 iterations; Holm correction). Secondary outcomes included median absolute error, root-mean-square error, standard deviation of PE, and proportions of eyes within ±0.25diopter (D) and ±0.50D.

Results

Included were 2550 patients (2550 eyes; mean age 74.0±10.0 years; 1068 male patients [41.9%]). Moussa produced a lower MAE (0.348 D) than Kane (0.359D), EVO (0.363D), PEARL-DGS (0.367D), K6 (0.367D), Hoffer-QST (0.377D), and BUII (0.379D; all p<.001). In short eyes (≤22.0mm), Moussa (0.412D) demonstrated lower error than K6 (p<.001), BUII (p<.001), Hoffer-QST (p=.008), EVO (p=.008), PEARL-DGS (p=.014), and Kane (p=.039). In long eyes (≥26.0 mm), Moussa (0.342 D) had lower error than Kane, BUII, Hoffer-QST (all p<.001), and K6 (p=.045), but not EVO (p=.068) or PEARL-DGS (p=.202).

Conclusions

The Moussa formula demonstrated high predictive accuracy across multiple biometry platforms, with statistically lower overall MAE than the comparator formulas. Absolute differences from the closest-performing formulas were modest, and ±0.50D outcomes were similar to Kane and EVO. These findings support Moussa as a clinically relevant contemporary option for IOL power calculation, with encouraging results in short and long eyes requiring further targeted validation.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.